The prevalence of cardiovascular disease by vascular bed and impact on healthcare costs in a large, real-world population with type 2 diabetes.
atherosclerotic cardiovascular disease
cerebrovascular disorders
coronary disease
epidemiology
peripheral vascular diseases
type 2 diabetes mellitus
vascular diseases
Journal
Endocrinology, diabetes & metabolism
ISSN: 2398-9238
Titre abrégé: Endocrinol Diabetes Metab
Pays: England
ID NLM: 101732442
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
30
05
2019
revised:
13
11
2019
accepted:
16
11
2019
entrez:
23
4
2020
pubmed:
23
4
2020
medline:
23
4
2020
Statut:
epublish
Résumé
The purpose of this study was to assess prevalence of atherosclerotic cardiovascular disease (ASCVD) according to number of affected vascular beds and the impact on healthcare utilization and costs in persons with type 2 diabetes mellitus (type 2 DM) and established ASCVD. In this retrospective, cross-sectional analysis, adults with type 2 DM and ASCVD in a large US administrative claims database were categorized by number of ASCVD-affected vascular beds (brain, heart, peripheral vasculature). Annual healthcare utilization and costs for 2015 were determined, including subgroup analyses by age group (18-44, 45-64, ≥65 years). Among 539 089 individuals with type 2 DM and ASCVD, 47.0% had ASCVD affecting >1 vascular bed. The most prevalent ASCVD diagnoses were acute coronary syndrome (26.6%), peripheral arterial disease (24.5%) and stroke (18.6%). Mean annual total healthcare costs per person increased with increasing number of vascular beds, from 1 ($17 741) to 2 ($25 877) to 3 ($33 412). A similar pattern of increased healthcare utilization with increasing number of vascular beds was observed. Among individuals with 1 affected vascular bed, mean total healthcare costs per person were comparable across age subgroups; however, if >1 vascular bed was affected, the mean total healthcare costs were highest in the youngest age cohort. These real-world data showed that almost half of individuals with type 2 DM and ASCVD had ASCVD affecting >1 vascular bed. A higher number of affected vascular beds were associated with higher mean total healthcare costs and utilization, with a disproportionate increase noted in younger relative to older people.
Identifiants
pubmed: 32318629
doi: 10.1002/edm2.106
pii: EDM2106
pmc: PMC7170457
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e00106Informations de copyright
© 2020 Novo Nordisk Inc.. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
R. Ganguly, M. Hersloev, J. Brett and T. Hobbs are current employees of Novo Nordisk Inc, the funding body for this study. F. M. M. Baeres is a current employee of Novo Nordisk A/S. W. Weng and S. X. Kong were employees of Novo Nordisk, Inc, during study conduct.
Références
Pharmacoeconomics. 2015 Aug;33(8):811-31
pubmed: 25787932
J Manag Care Spec Pharm. 2018 Mar;24(3):280-290
pubmed: 29485954
Diabetes Care. 2013 Apr;36(4):1033-46
pubmed: 23468086
World J Diabetes. 2015 Oct 10;6(13):1246-58
pubmed: 26468341
Diabetes Care. 2018 May;41(5):917-928
pubmed: 29567642
Value Health. 2018 Jul;21(7):881-890
pubmed: 30005761
Diabetes Care. 2017 Jan;40(Suppl 1):S75-S87
pubmed: 27979896
Int J Hypertens. 2013;2013:653789
pubmed: 23533715
Arterioscler Thromb Vasc Biol. 2017 Feb;37(2):191-204
pubmed: 27908890
World J Diabetes. 2015 Jul 10;6(7):961-9
pubmed: 26185603
Circ Cardiovasc Qual Outcomes. 2008 Sep;1(1):38-45
pubmed: 20031786
Eur Heart J. 2009 Oct;30(19):2318-26
pubmed: 19720633
Endocrinol Diabetes Metab. 2019 May 22;2(3):e00076
pubmed: 31294089
Clin Diabetes Endocrinol. 2020 Mar 4;6:5
pubmed: 32158550